TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1719736
Drug: 10% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydroxyethyl starch solution (HAES 200/0.62)
Study: 1719736
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch solution (HES 200.000/0.62)
Study: 30673866
Drug: Fludroxycortide cream
Normalized name: fludroxycortide
DrugBank: Flurandrenolide (DB00846)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fludroxycortide cream (0.125 mg/g) applied three times a day for up to 6 weeks, associated with lip sunscreen (LS) before sun exposure.
Study: 30673866
Drug: Fludroxycortide cream
Normalized name: fludroxycortide
DrugBank: Flurandrenolide (DB00846)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fludroxycortide cream (0.125 mg/g) applied three times a day for up to 6 weeks.
Study: 21185503
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and 80 mg
Study: 21185503
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (not specified treatment)
Study: 19552619
Drug: Linagliptin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (10 mg/day)
Study: 19552619
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg three times daily)
Study: 19552619
Drug: Linagliptin and
Normalized name: linagliptin and empagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and Metformin co-administration
Study: 15025737
Drug: Cetirizine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine administered orally in various formulations and in single and multiple dosage regimens
Study: 11965201
Drug: Rofecoxib (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (average 24.7 mg daily)
Study: 11965201
Drug: NSAIDs (ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ibuprofen 800 mg thrice daily, diclofenac 50 mg thrice daily, nabumetone 1500 mg daily)
Study: 10023325
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion cisplatin (arm B)
Study: 25664387
Drug: Reduced substance
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced substance use (drugs)
Study: 25664387
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to additional treatment modalities
Study: 25664387
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to prescribed medication
Study: 18556609
Drug: Randomized encouragement
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized encouragement designs where participants are randomly invited to participate in treatment conditions but can choose whether to receive treatment.
Study: 18556609
Drug: Quantitative assignment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative assignment designs where treatment is assigned based on a quantitative measure (e.g., need, merit, risk).
Study: 18556609
Drug: Observational studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observational studies where treatment assignment is unknown and presumed to be nonrandom.
Study: 16778647
Drug: Latanoprost therapy
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost therapy for 1 month
Study: 16778647
Drug: Brimonidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine treatment for nonresponders
Study: 16778647
Drug: Timolol treatment
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol treatment for nonresponders
Study: 16778647
Drug: Pilocarpine treatment
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine treatment for nonresponders
Study: 12970829
Drug: Therapy-based studies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy-based studies
Study: 12970829
Drug: Drug-based studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-based studies
Study: 11573055
Drug: GRF glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRF glue as a topical haemostatic agent
Study: 9572319
Drug: Antisecretory drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisecretory drugs in H. pylori-positive peptic ulcer patients taking NSAIDs
Study: 7875101
Drug: Transvaginal intra-amniotic
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal intra-amniotic injection of methotrexate (MTX, 100 mg)
Study: 2851173
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin and etoposide [VP‐16]) plus radiation therapy (30 + 20 Gy split course)
Study: 2851173
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin and etoposide [VP‐16]) plus radiation therapy (30 + 20 Gy split course) plus lonidamine (LND)
Study: 2851173
Drug: Chemotherapy/radiation (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/radiation (arm A)
Study: 2851173
Drug: Chemotherapy/radiation/LND (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/radiation/LND (arm B)
Study: 2851173
Drug: Chemotherapy/radiation/LND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/radiation/LND
Study: 30553135
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management (intentional early delivery 24 hours after second steroid dose)
Study: 23919808
Drug: Multi-component physical
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component physical activity intervention including indoor physical activity, recess, daily lessons, and social environment
Study: 21195573
Drug: Indapamide 1.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.5mg sustained release and 2.5mg immediate release formulations
Study: 14616224
Drug: Dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase or augmentation with lithium or desipramine
Study: 9772437
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg orally q12h for 2 days followed by misoprostol 25 micrograms intravaginally q12h
Study: 9772437
Drug: Sodium prasterone
Normalized name: prasterone sodium sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium prasterone sulfate 200 mg intravenously qd for 3 days followed by oxytocin intravenous infusion
Study: 8380487
Drug: Milacemide (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide (1,200 mg, single oral dose)
Study: 31290990
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) - 14 RCTs (1 ipilimumab, 5 pembrolizumab, 5 nivolumab, 2 atezolizumab, 1 durvalumab)
Study: 31290990
Drug: Non-immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-immune checkpoint inhibitors - 86 RCTs (74 targeted therapy, 8 chemotherapy, 3 hormone therapy, 1 radiopharmaceutical)
Study: 31290990
Drug: Non-immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-immune checkpoint inhibitors
Study: 26556079
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (including methylphenidate)
Study: 26556079
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drug therapy and perceptual motor training
Study: 16185211
Drug: Methadone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 50 mg
Study: 16185211
Drug: Methadone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 100 mg
Study: 16185211
Drug: Methadone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 150 mg
Study: 14621086
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 microg pressurised metered dose inhaler
Study: 10376691
Drug: Lindane (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindane (1% topical application)
Study: 1839379
Drug: TAP-144-SR (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR (all doses)
Study: 1839379
Drug: TAP-144-SR (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR (doses >30 micrograms/kg)
Study: 27415850
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) consisting of 8 telephone sessions, a patient education book, and a stress management procedure on compact disc.
Study: 14527931
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of 50 microm/m2 of G‐CSF (SI)
Study: 14527931
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous injection of 50 microm/m2 of G‐CSF for 24 h (CI)
Study: 21777897
Drug: 3.9 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9 g/d tranexamic acid
Study: 21777897
Drug: 1.95 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.95 g/d tranexamic acid
Study: 19459424
Drug: Ingavirin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingavirin (90 mg once daily for 5 days)
Study: 19459424
Drug: Arbidol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbidol (200 mg 4 times a day for 5 days)
Study: 14713135
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg/d) plus contingency management
Study: 14713135
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg/d) plus noncontingent voucher control
Study: 10890475
Drug: Hemofiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Study: 10890475
Drug: Hemofiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Study: 10890475
Drug: No hemofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Study: 10890475
Drug: No hemofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Study: 8851621
Drug: Ceftriaxone 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1,000 mg intravenously 30 min before anesthesia (group 1)
Study: 8851621
Drug: Ceftriaxone 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1,000 mg intravenously followed by a second 1,000 mg at initiation of cardiopulmonary bypass (group 2)
Study: 6422868
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain enriched therapy at 0.7 gm/kg/day of branched chain amino acids
Study: 6422868
Drug: Balanced parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced parenteral nutrition with 1.5 gm/kg/day of amino acids, 30 calories/kg/day of glucose, and 7 calories/kg/day of fat
Study: 20127537
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg i.v. Lornoxicam
Study: 15481277
Drug: Heavy progressive
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy progressive resistance training (RE) twice a week for 12 weeks
Study: 9541173
Drug: Night-time continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time continuous subcutaneous insulin infusion (CSII) therapy
Study: 2656442
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g piracetam/day i.v. followed by 3 x 800 mg/day p.o. for 8 weeks
Study: 29548719
Drug: Dapagliflozin/metformin XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin/metformin XR FCDP (10/1000 mg)
Study: 29548719
Drug: Individual component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual component tablets (dapagliflozin [10 mg] plus metformin XR [2 × 500 mg])
Study: 28895887
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose (HD: high dose)
Study: 28895887
Drug: 5X/week (MD:
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5X/week (MD: Moderate Dose)
Study: 28895887
Drug: 3X/week (LD:
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3X/week (LD: Low Dose)
Study: 20921029
Drug: Intermittent high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-intensity therapy (Group A): 3 two-month blocks, 4 sessions per week (30-45 minutes each), total 96 sessions
Study: 20921029
Drug: Continuous low-intensity
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low-intensity therapy (Group B): 2 sessions per week (30-45 minutes each), total 104 sessions
Study: 20921029
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (Continuous low-intensity therapy)
Study: 16396977
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg/day)
Study: 15335093
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate gel
Study: 15335093
Drug: Neem extract
Normalized name: neem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neem extract gel
Study: 11071803
Drug: High-dose lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lisinopril (32.5-35 mg/day)
Study: 11071803
Drug: Low-dose lisinopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lisinopril (2.5-5 mg/day)
Study: 9186877
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and Morphine (N = 12)
Study: 8084977
Drug: Lithium (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (maintenance therapy)
Study: 8084977
Drug: Nonpharmacologic approaches
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic approaches (ECT, sleep deprivation, light therapy)
Study: 24968129
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 20-2 ppm for 24 days
Study: 24968129
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 2 ppm
Study: 19144162
Drug: Therapy online
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy online
Study: 12930486
Drug: Anxiety-blocker (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiety-blocker (placebo purported to block anxiety)
Study: 1665179
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Study: 1665179
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Study: 26106632
Drug: Intravenous midazolam‐ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous midazolam‐ketamine
Study: 26106632
Drug: Intravenous midazolam‐fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous midazolam‐fentanyl
Study: 12972723
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment for two months followed by semi-standardized acupuncture (75 patients, waiting list control)
Study: 10755576
Drug: rhGH (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.05 mg/kg subcutaneously)
Study: 6443576
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of an LHRH agonistic analogue by parenteral and/or intranasal routes
Study: 30341003
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (6.6 mU/minute)
Study: 30341003
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin (3.3 mU/minute)
Study: 29408705
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HyperBOT) at 2.5 ATA for 60 minutes
Study: 29408705
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen therapy (NormBOT) at 1.5 ATA
Study: 24094827
Drug: Recovery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery with hyperglycemia after hypoglycemia with vitamin C infusion
Study: 11172843
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) plus tibolone (2.5 mg/d orally)
Study: 11172843
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) plus tibolone
Study: 11172843
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) plus placebo (1 tablet per day orally)
Study: 8169458
Drug: Subcutaneous 200-ng
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 200-ng bolus of octreotide
Study: 28536184
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g casein protein with 2 g free leucine (PRO+leu)
Study: 28536184
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g casein protein without 2 g free leucine (PRO)
Study: 24285757
Drug: Alvimopan (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan (with preoperative dose)
Study: 24285757
Drug: Alvimopan (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan (without preoperative dose)
Study: 18932221
Drug: Sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin dihydrochloride (5, 10, or 20 mg/kg/day)
Study: 8907720
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone (NEF) 200 mg under fasting conditions
Study: 8907720
Drug: Nefazodone (NEF)
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone (NEF) 200 mg after a high‐fat breakfast
Study: 24603072
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg r‐tPA
Study: 21197501
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of single implants placed in extraction sockets
Study: 21197501
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of single implants placed in healed ridges
Study: 21197501
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants (both groups)
Study: 6111525
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of atenolol (Tenormin) for 3 days
Study: 30447668
Drug: Intramuscular cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cholecalciferol (vitamin D)
Study: 26829509
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous tranexamic acid
Study: 24688085
Drug: beta‐hydroxy‐beta‐methylbutyrate/arginine/glutamine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐hydroxy‐beta‐methylbutyrate/arginine/glutamine supplement (Group A)
Study: 18551818
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g, single i.v. administration)
Study: 18551818
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g, single i.v. administration)
Study: 15669214
Drug: Serotonin-selective reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin-selective reuptake inhibitors (SSRIs)
Study: 11972726
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and Fluoxetine
Study: 27522310
Drug: Bag-valve-mask device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bag-valve-mask device with oxygen at 15 L/min (BVM-15)
Study: 27522310
Drug: Nonrebreather mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonrebreather mask with oxygen at 15 L/min (NRB-15)
Study: 21560012
Drug: PVR >
Normalized name: Pulmonary Vascular Resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVR > 100 cc at 12 months
Study: 12766654
Drug: Bupivacaine 0.1%
Normalized name: BUPIVACAINE 0.1%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.1% with 5 microg/ml fentanyl
Study: 12766654
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% with 5 microg/ml fentanyl
Study: 11463605
Drug: UTP 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: UTP 20 mg
Study: 11463605
Drug: UTP 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UTP 100 mg
Study: 3118327
Drug: Lactose solution
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose solution (35 g)
Study: 3118327
Drug: Glucose +
Normalized name: Fora Test N'GO Advance Blood Glucose + B-Ketone Monitoring System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose + galactose solution (17.5 + 17.5 g)
Study: 31205105
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments for angina
Study: 26241948
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine with buffer
Study: 16028125
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine
Study: 21196104
Drug: Fluticasone/formoterol (500/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol (500/20 μg, b.i.d.)